{"organizations": [], "uuid": "b79727a8c95aa2060e33862131bfeaf7a1730ad5", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180501.html", "section_title": "Archive News &amp; Video for Tuesday, 01 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-ironwood-pharmaceuticals-to-separa/brief-ironwood-pharmaceuticals-to-separate-into-two-independent-publicly-traded-companies-idUSASC09YKD", "country": "US", "domain_rank": 408, "title": "BRIEF-Ironwood Pharmaceuticals To Separate Into Two Independent, Publicly Traded Companies", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-01T20:03:00.000+03:00", "replies_count": 0, "uuid": "b79727a8c95aa2060e33862131bfeaf7a1730ad5"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-ironwood-pharmaceuticals-to-separa/brief-ironwood-pharmaceuticals-to-separate-into-two-independent-publicly-traded-companies-idUSASC09YKD", "ord_in_thread": 0, "title": "BRIEF-Ironwood Pharmaceuticals To Separate Into Two Independent, Publicly Traded Companies", "locations": [], "entities": {"persons": [], "locations": [{"name": "separ", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "ironwood pharmaceuticals inc", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 1 (Reuters) - Ironwood Pharmaceuticals Inc:\n* IRONWOOD PHARMACEUTICALS ANNOUNCES INTENT TO SEPARATE SOLUBLE GUANYLATE CYCLASE (SGC) BUSINESS FROM COMMERCIAL AND GASTROINTESTINAL BUSINESS\n* IRONWOOD PHARMACEUTICALS INC - SEPARATION EXPECTED TO RESULT IN TWO INDEPENDENT, PUBLICLY TRADED COMPANIES\n* IRONWOOD PHARMACEUTICALS INC - EXPECTS TO INCUR CHARGES RELATED TO TRANSACTION\n* IRONWOOD - ASSETS EXPECTED TO CONTINUE TO INCLUDE THREE IN-MARKET PRODUCTS AND TWO DEVELOPMENT CANDIDATES TARGETING GI DISEASES AND ABDOMINAL PAIN\n* IRONWOOD - ANTICIPATES BEING PROFITABLE WITH “STRONG REVENUE GROWTH” FROM ITS IN-MARKET PRODUCTS FOLLOWING SEPARATION\n* IRONWOOD PHARMACEUTICALS INC - PLANS TO HAVE SEPARATE BOARDS AND MANAGEMENT TEAMS FOR EACH BUSINESS\n* IRONWOOD - ALL OF IRONWOOD’S CURRENT LINACLOTIDE COLLABORATIONS ARE EXPECTED TO REMAIN WITH IRONWOOD\n* IRONWOOD PHARMACEUTICALS INC - INTENDS TO TRANSITION EMPLOYEES TO NEW BUSINESSES AS ORGANIZATION DESIGN IS COMPLETED OVER COMING MONTHS\n* IRONWOOD PHARMA - PLANS TO PROVIDE UPDATE ON IMPACT OF TRANSACTION CHARGES ON 2018 GUIDANCE DURING Q2 INVESTOR UPDATE\n* IRONWOOD PHARMACEUTICALS INC - IRONWOOD EXPECTED TO RETAIN U.S. RIGHTS TO LESINURAD FRANCHISE FOR UNCONTROLLED GOUT\n* IRONWOOD PHARMACEUTICALS INC - AFTER SEPARATION, COMMERCIAL BUSINESS TO CONTINUE TO BE NAMED IRONWOOD, NAME OF RESEARCH AND DEVELOPMENT CO. TO BE ANNOUNCED LATER Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-01T20:03:00.000+03:00", "crawled": "2018-05-02T16:17:54.002+03:00", "highlightTitle": ""}